How Aerska Aims to Systemically Deliver RNA Medicines to the Brain

Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, led by Jack O’Meara, Stuart Milstein, Dave Hardwicke, and others, has raised $39 million in Series A financing led by EQT Dementia Fund and age1, with participation from Iaso Ventures, alongside existing investors. Total funding has reached $60 million, following a seed round in October 2025.

The funding will support the development of brain shuttle technology to enhance RNAi therapeutic delivery across the blood-brain barrier for neurological disease treatment.

Proceeds will support further development of Aerska’s antibody-oligo conjugate (AOC) platform, advancing systemically delivered RNAi therapeutics for neurological diseases toward clinical testing.

Aerska’s AOC platform enables systemically delivered RNA medicines to reach the brain and address neurological diseases at their source. Using proprietary “brain shuttle” technology to cross the blood-brain barrier, the platform supports intravenous or subcutaneous administration, achieving widespread brain distribution and durable target gene knockdown, opening new therapeutic possibilities for CNS disorders.

Jack O’Meara, CEO & Co-Founder of Aerska, said the ability to systemically deliver RNAi therapies to the brain opens a new approach for treating neurodegeneration. Partnership with EQT Dementia Fund strengthens the path to the clinic, aiming to develop meaningful therapies for genetically driven Alzheimer’s and other serious brain disorders.

Philip Scheltens, Partner and Head of the Dementia Fund at EQT Life Sciences, said Aerska’s approach offers hope for preserving cognitive function and quality of life. By targeting genetic forms of neurological disease with upstream intervention, the team aims to transform outcomes for populations underserved by current therapies, and EQT looks forward to advancing this platform alongside them.

As part of the financing, Arno de Wilde (Managing Director, EQT), Philip Scheltens (Partner and Head of the Dementia Fund, EQT), and Alex Colville (General Partner, age1) will join Aerska’s Board of Directors.